Composition: | Dapagliflozin 10mg + Sitagliptin 100mg + Metformin (ER) 500mg |
Packaging: | 10x10 |
• Play a significant role in reducing hba1c in uncontrolled type 2 diabetes • Improving patient compliance by reducing pill burden • Offers advantage of lower risk of hypoglycemia, better pancreatic beta cell protection, cardiac & renal benefit & better tolerability. • The triple-drug FDC has superior efficacy in terms of glycemic control a compared to dual drug combination.